OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Phase 3
Terminated
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Opthea Limited
- Target Recruit Count
- 986
- Registration Number
- NCT04757610
- Locations
- 🇧🇷
ShORe Investigational site, Blumenau, Santa Catarina, Brazil
🇮🇹ShORe Investiagational Site, Genova, Italy
🇺🇸ShORe Investiagtional Site, Poway, California, United States
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
Phase 3
Terminated
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Biological: 2.0 mg OPT-302Biological: 2.0 afliberceptProcedure: Sham
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Opthea Limited
- Target Recruit Count
- 998
- Registration Number
- NCT04757636
- Locations
- 🇬🇧
COAST Investigational Site, London, United Kingdom
🇺🇸COAST Investigational site, Shirley, New York, United States
A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema
Phase 1
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Opthea Limited
- Target Recruit Count
- 153
- Registration Number
- NCT03397264
- Locations
- 🇱🇻
Opthea Investigational Site, Riga, Latvia
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
Phase 2
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Biological: OPT-302Biological: ranibizumabOther: sham intravitreal injection
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Opthea Limited
- Target Recruit Count
- 366
- Registration Number
- NCT03345082
- Locations
- 🇬🇧
Opthea Investigational Site, Wolverhampton, United Kingdom
🇺🇸Opthea Study Site, Sacramento, California, United States
🇵🇱Opthea Investigationa Site, Lublin, Poland
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
Phase 1
Completed
- Conditions
- Eye DiseasesMacular DegenerationRetinal DiseasesRetinal DegenerationNeovascularization, Pathologic
- Interventions
- Drug: Lucentis™
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Opthea Limited
- Target Recruit Count
- 51
- Registration Number
- NCT02543229
- Locations
- 🇺🇸
Opthea Investigative Site, Willow Park, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath